Will the FDA Regulate Just Genetic Risk Data, or All Risk Data?

The latest in the 23andme versus FDA saga, in which the FDA halted 23andme from offering health-risk analyses of the genotyping service the company sells, comes in a commentary published yesterday in Nature. The commentary’s authors, Robert Green of Harvard Medical School and Nita Farahany of Duke Law School, address a key question raised by the FDA’s […]

Continue reading →